Latest Conference Articles

November 10th 2019, 5:20am

PER® New York Lung Cancer Symposium

Neoadjuvant immunotherapy can offer promise to patients with resectable non–small cell lung cancer, but further investigation is required for optimal use, Tina Cascone, MD, PhD, said in a presentation during the 14th Annual New York Lung Cancers Symposium®.

November 10th 2019, 4:33am

PER® New York Lung Cancer Symposium

Based on efficacy, tolerability, and practicality, neoadjuvant therapy in lung cancer offers significant advantages over adjuvant treatment, said Jamie E. Chaft, MD, in a presentation during the 14th Annual New York Lung Cancers Symposium®. However, she added, adjuvant treatment predominantly remains the standard of care at many cancer centers, she said.

November 9th 2019, 8:00pm

PER® New York Lung Cancer Symposium

Benjamin P. Levy, MD, discusses therapeutic strategies for patients with oncogenic-driven and nondriver non–small cell lung cancer.

October 26th 2019, 6:03pm

Hairy Cell Leukemia Foundation Annual Conference

Robert J. Kreitman, MD, discusses the role of minimal residual disease (MRD) status in hairy cell leukemia, how to effectively test for MRD, and how the combination of moxetumomab pasudotox and rituximab could alter the treatment landscape.

October 26th 2019, 1:18am

Hairy Cell Leukemia Foundation Annual Conference

The standard of care for the frontline treatment of patients with hairy cell leukemia has been purine nucleoside analogs, including pentostatin and cladribine; however, investigators are challenging this treatment in a phase II clinical trial with a targeted therapy that may provide similar benefit with fewer toxicities.

October 26th 2019, 12:00am

Hairy Cell Leukemia Foundation Annual Conference

Agnieszka Janus, MD, PhD, shares perspective on three cases of patients with HCL who were given vemurafenib after having progressed on multiple lines of treatment.

October 25th 2019, 11:52pm

Hairy Cell Leukemia Foundation Annual Conference

Kerry Rogers, MD, discusses the potential of ibrutinib (Imbruvica) in hairy cell leukemia, emerging treatment options such as moxetumomab pasudotox (Lumoxiti), and next steps and challenges in the field.

October 25th 2019, 7:37pm

Hairy Cell Leukemia Foundation Annual Conference

Robert J. Kreitman, MD, discusses the association between minimal residual disease-negativity and complete remission durations in patients with hairy cell leukemia treated with moxetumomab pasudotox.

October 25th 2019, 6:16pm

Hairy Cell Leukemia Foundation Annual Conference

Justin Taylor, MD, discusses the design of an ongoing phase II clinical trial evaluating the combination of frontline vemurafenib plus obinutuzumab in patients with hairy cell leukemia.

October 25th 2019, 4:35pm

Hairy Cell Leukemia Foundation Annual Conference

James Blachly, MD, discusses the role of circulating tumor DNA as a biomarker for patients with hairy cell leukemia.

October 25th 2019, 3:21am

Hairy Cell Leukemia Foundation Annual Conference

Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.

October 25th 2019, 2:54am

Hairy Cell Leukemia Foundation Annual Conference

Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.

October 24th 2019, 11:23pm

Hairy Cell Leukemia Foundation Annual Conference

Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.

October 7th 2019, 2:47am

Lynn Sage Breast Cancer Symposium

Immunotherapy may finally be taking center stage in breast cancer, although much work remains to be done.

October 7th 2019, 1:53am

Lynn Sage Breast Cancer Symposium

There is an unprecedented array of therapeutic options for patients with triple-negative breast cancer, with more approaches on the horizon.

October 7th 2019, 12:35am

Lynn Sage Breast Cancer Symposium

C. Kent Osborne, MD, discusses the important take home message for physicians treating patients with HER2-positive breast cancer. Osborne says the role of HER2-positivity is complicated.

October 6th 2019, 9:26pm

Lynn Sage Breast Cancer Symposium

Hope S. Rugo, MD, discusses the latest advancements in the treatment landscape for patients with TNBC and highlights some data from clinical trials presented at the 2019 ESMO Congress.

October 6th 2019, 5:00pm

Lynn Sage Breast Cancer Symposium

Andrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.

October 6th 2019, 12:28am

Lynn Sage Breast Cancer Symposium

In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.

October 5th 2019, 11:42pm

Lynn Sage Breast Cancer Symposium

In contemporary breast cancer clinical practice, the correlation between achieving a pathologic complete response after neoadjuvant chemotherapy and significantly improved outcomes after chemotherapy has been well established. However, in a discussion at the 2019 Lynn Sage Breast Cancer Symposium, William J. Gradishar, MD, cautioned colleagues that there is more to the story when one looks at long-term data in these patients.